Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol

Pal Pacher, Alex Nivorozhkin, Csaba Szabó

    Research output: Contribution to journalReview article

    738 Scopus citations

    Abstract

    The prototypical xanthine oxidase (XO) inhibitor allopurinol, has been the cornerstone of the clinical management of gout and conditions associated with hyperuricemia for several decades. More recent data indicate that XO also plays an important role in various forms of ischemic and other types of tissue and vascular injuries, inflammatory diseases, and chronic heart failure. Allopurinol and its active metabolite oxypurinol showed considerable promise in the treatment of these conditions both in experimental animals and in small-scale human clinical trials. Although some of the beneficial effects of these compounds may be unrelated to the inhibition of the XO, the encouraging findings rekindled significant interest in the development of additional, novel series of XO inhibitors for various therapeutic indications. Here we present a critical overview of the effects of XO inhibitors in various pathophysiological conditions and also review the various emerging therapeutic strategies offered by this approach.

    Original languageEnglish (US)
    Pages (from-to)87-114
    Number of pages28
    JournalPharmacological reviews
    Volume58
    Issue number1
    DOIs
    StatePublished - Mar 1 2006

    ASJC Scopus subject areas

    • Molecular Medicine
    • Pharmacology

    Fingerprint Dive into the research topics of 'Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol'. Together they form a unique fingerprint.

  • Cite this